Eiger BioPharmaceuticals: FDA Approval of Zokinvy™ (Ionafarnib)

CordenPharma congratulates Eiger BioPharmaceuticals on their recent FDA Approval of Zokinvy™ (lonafarnib): The First Treatment for Progeria Syndrome and Processing-Deficient Progeroid Laminopathies.

CordenPharma Colorado (Boulder, US) is honored to supply the Active Pharmaceutical Ingredient (API) in Zokinvy™ to support this disease-modifying agent that has demonstrated a statistically significant survival benefit in children and young adults with Hutchinson-Gilford Progeria Syndrome. Read Eiger’s full press release here.

CordenPharma congratulates Eiger BioPharmaceuticals on their recent FDA Approval of Zokinvy (lonafarnib): The First Treatment for Progeria Syndrome and Processing-Deficient Progeroid Laminopathies.